Lupus Foundation of America Statement on Successful Results of Phase IIB Clinical Trial of Voclosporin

Trial results offer hope of a more effective and tolerable treatment option to manage lupus-related kidney disease.Today Aurinia Pharmaceutical Company announced positive top-line results of a Phase IIB clinical study of voclosporin, a potential new therapy option for people with active lupus nephritis (lupus-related kidney disease).  The study met its primary endpoint of achieving complete remission in a statistically significant number of study participants who received voclosporin. More details about this study are available through the company’s news release